AnaptysBio (NASDAQ:ANAB) CEO Daniel Faga Sells 17,679 Shares

AnaptysBio, Inc. (NASDAQ:ANAB) CEO Daniel Faga sold 17,679 shares of the firm’s stock in a transaction that occurred on Friday, March 27th. The stock was sold at an average price of $61.61, for a total transaction of $1,089,203.19. Following the completion of the transaction, the chief executive officer directly owned 495,965 shares in the company, valued at approximately $30,556,403.65. The trade was a 3.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Daniel Faga also recently made the following trade(s):

• On Thursday, January 8th, Daniel Faga sold 14,281 shares of AnaptysBio stock. The shares were sold at an average price of $44.71, for a total transaction of $638,503.51.
• On Wednesday, January 7th, Daniel Faga sold 9,202 shares of AnaptysBio stock. The stock was sold at an average price of $45.11, for a total transaction of $415,102.22.
• On Monday, January 5th, Daniel Faga sold 15,309 shares of AnaptysBio stock. The stock was sold at an average price of $43.26, for a total transaction of $662,267.34.

AnaptysBio Price Performance

Shares of ANAB stock opened at $57.40 on Friday. AnaptysBio, Inc. has a 1 year low of $15.40 and a 1 year high of $68.39. The firm has a fifty day moving average price of $55.30 and a 200-day moving average price of $43.49. The company has a market cap of $1.65 billion, a price-to-earnings ratio of -110.38 and a beta of 0.32.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, March 3rd. The biotechnology company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $0.89 by $0.69. The company had revenue of $108.25 million for the quarter, compared to analysts’ expectations of $87.09 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 5.64%. Equities research analysts expect that AnaptysBio, Inc. will post -6.08 EPS for the current year.

AnaptysBio announced that its Board of Directors has approved a share repurchase program on Friday, March 27th that authorizes the company to repurchase $100,000.00 billion in shares. This repurchase authorization authorizes the biotechnology company to buy up to 5,352,316.2% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s leadership believes its stock is undervalued.

Hedge Funds Weigh In On AnaptysBio

A number of hedge funds have recently made changes to their positions in ANAB. Smartleaf Asset Management LLC grew its position in shares of AnaptysBio by 5,864.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 821 shares in the last quarter. Larson Financial Group LLC raised its stake in AnaptysBio by 54.6% during the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 473 shares during the period. Bessemer Group Inc. lifted its holdings in AnaptysBio by 950.0% in the 3rd quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 1,292 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in AnaptysBio by 175.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,377 shares in the last quarter. Finally, Osaic Holdings Inc. boosted its stake in AnaptysBio by 11,630.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 2,326 shares during the period.

Wall Street Analysts Forecast Growth

ANAB has been the topic of a number of analyst reports. HC Wainwright lifted their price objective on AnaptysBio from $51.00 to $66.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Truist Financial raised shares of AnaptysBio to a “hold” rating in a report on Wednesday. UBS Group raised their target price on shares of AnaptysBio from $70.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday, March 17th. Guggenheim reaffirmed a “buy” rating on shares of AnaptysBio in a report on Thursday, December 18th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AnaptysBio in a research report on Wednesday, January 21st. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $78.44.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.